92 related articles for article (PubMed ID: 11761966)
1. [Hepatocyte targeted MR contrast agent--Gd-BOPTA(E-7155)].
Kuwatsuru R; Katayama H
Nihon Rinsho; 2001 Oct; 59 Suppl 6():323-7. PubMed ID: 11761966
[No Abstract] [Full Text] [Related]
2. Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight.
Pastor CM
Radiology; 2010 Nov; 257(2):589. PubMed ID: 20959554
[No Abstract] [Full Text] [Related]
3. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
4. MultiHance: help or hype?
Bartolozzi C; Spinazzi A
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S151-9. PubMed ID: 10608411
[TBL] [Abstract][Full Text] [Related]
5. [Early phase II trial of Gd-BOPTA (E7155) for the MR imaging of liver tumors].
Kuwatsuru R; Kadoya M; Tanimoto A; Hirohashi S; Katayama H
Nihon Igaku Hoshasen Gakkai Zasshi; 1996 Jul; 56(8):555-63. PubMed ID: 8797346
[TBL] [Abstract][Full Text] [Related]
6. Liver lesion characterization: the wrong choice of contrast agent can mislead the diagnosis of hemangioma.
Pradella S; Lucarini S; Colagrande S
AJR Am J Roentgenol; 2012 Nov; 199(5):W662. PubMed ID: 23096214
[No Abstract] [Full Text] [Related]
7. Hepatocyte-specific magnetic resonance imaging contrast agents.
Fidler J; Hough D
Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
[No Abstract] [Full Text] [Related]
8. Contrast enhanced MR-guided biopsy of hepatocellular carcinoma.
König CW; Trübenbach J; Fritz J; Lauer UM; Claussen CD; Pereira PL
Abdom Imaging; 2004; 29(1):71-6. PubMed ID: 15160756
[TBL] [Abstract][Full Text] [Related]
9. Clinical late phase II trials of MultiHance (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan.
Kuwatsuru R; Kadoya M; Ohtomo K; Tanimoto A; Hirohashi S; Murakami T; Tanaka Y; Yoshikawa K; Katayama H
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S65-74. PubMed ID: 10608400
[TBL] [Abstract][Full Text] [Related]
10. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A; Paci E
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
[TBL] [Abstract][Full Text] [Related]
11. Hollow fiber bioreactor: new development for the study of contrast agent transport into hepatocytes by magnetic resonance imaging.
Planchamp C; Ivancevic MK; Pastor CM; Vallée JP; Pochon S; Terrier F; Mayer JM; Reist M
Biotechnol Bioeng; 2004 Mar; 85(6):656-65. PubMed ID: 14966807
[TBL] [Abstract][Full Text] [Related]
12. [A comparative study between Gd-BOPTA, a biliary excretion contrast medium, and Gd-DTPA in the magnetic resonance imaging of the rat liver].
Patrizio G; Pavone P; Cardone G; Pietroletti R; Passariello R; Tettamanti E; Musu C; Felder E
Radiol Med; 1990 May; 79(5):458-62. PubMed ID: 2359853
[TBL] [Abstract][Full Text] [Related]
13. Direct evidence of the temperature dependence of Gd-BOPTA transport in the intact rat liver.
Planchamp C; Beyer GJ; Slosman DO; Terrier F; Pastor CM
Appl Radiat Isot; 2005 Jun; 62(6):943-9. PubMed ID: 15799874
[TBL] [Abstract][Full Text] [Related]
14. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
15. MR imaging of CNS tumors: are all contrast agents created the same?
Essig M
Neuroradiology; 2006 Apr; 48 Suppl 1():3-8. PubMed ID: 16699847
[TBL] [Abstract][Full Text] [Related]
16. AJR teaching file: incidental hepatic mass.
Beaty SD; Silva AC; Depetris G
AJR Am J Roentgenol; 2008 Jun; 190(6 Suppl):S62-4. PubMed ID: 18492933
[No Abstract] [Full Text] [Related]
17. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of different MRI sequences with and without application of Gd-BOPTA as follow-up after LITT].
Pech M; Spors B; Wieners G; Warschewske G; Beck A; Cho C; Fischbach F; Ricke J
Rofo; 2004 Apr; 176(4):550-5. PubMed ID: 15088180
[TBL] [Abstract][Full Text] [Related]
19. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents.
Giesel FL; von Tengg-Kobligk H; Wilkinson ID; Siegler P; von der Lieth CW; Frank M; Lodemann KP; Essig M
Invest Radiol; 2006 Mar; 41(3):222-8. PubMed ID: 16481904
[TBL] [Abstract][Full Text] [Related]
20. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
Jeon TY; Kim SH; Lee WJ; Lim HK
Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
